Hong Zhang

发表

Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance.

Daowen Wang, Xuefeng Yu, S. Shao, 2015, The Journal of clinical endocrinology and metabolism.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

B. Zinman, C. Cannon, B. Brenner, 2019, The New England journal of medicine.

Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.

A. Levin, M. Jardine, V. Perkovic, 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.

B. Zinman, C. Cannon, A. Levin, 2020, American heart journal.

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

B. Zinman, C. Cannon, A. Levin, 2020, Journal of the American Society of Nephrology : JASN.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

B. Zinman, C. Cannon, B. Brenner, 2019, Circulation.

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

B. Zinman, C. Cannon, A. Levin, 2020, Kidney international.

Association Between the Lipid Profile and Renal Dysfunction in the Heart Failure Patients

Hong Zhang, Fu-qiang Liu, Ling Zhu, 2019, Kidney and Blood Pressure Research.

Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

David W. Johnson, A. Levin, V. Jha, 2022, JAMA.

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.

B. Zinman, C. Cannon, A. Levin, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.

B. Zinman, C. Cannon, A. Levin, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Association between plasma phosphorus and renal outcome: A prospective cohort of patients majorly with glomerulonephritis

J. Lv, Luxia Zhang, Jinwei Wang, 2017, Nephrology.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

B. Zinman, C. Cannon, A. Levin, 2019, Circulation.

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

B. Zinman, C. Cannon, A. Levin, 2022, Journal of the American Heart Association.

Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial

A. Levin, K. Mahaffey, G. Bakris, 2022, Journal of diabetes research.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

B. Zinman, C. Cannon, B. Brenner, 2017, American Journal of Nephrology.

Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis

H. Tighiouart, A. Rodgers, V. Perkovic, 2013, Canadian Medical Association Journal.

Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis.

J. Lv, Luxia Zhang, Jinwei Wang, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Original Investigation Effect of Statins on Kidney Disease Outcomes: A Systematic Review and Meta-analysis

J. Lv, Luxia Zhang, Jinwei Wang, 2016 .

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials.

V. Perkovic, T. Ninomiya, J. Lv, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis.

F. Song, V. Perkovic, J. Lv, 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

M. Jardine, V. Perkovic, A. Cass, 2013, European heart journal.

The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.

B. Zinman, A. Levin, K. Mahaffey, 2022, Diabetes & metabolism.

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.

B. Zinman, A. Levin, K. Mahaffey, 2023, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Efficacy and Safety of Electrical Myostimulation for Sedentary Elderly People at Risk of Primary Sarcopenia: A Systematic Review and Meta-Analysis

Hong Zhang, Wen Zhong, Yuan Tian, 2020 .

Original Investigation Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials

V. Perkovic, T. Ninomiya, J. Lv, 2015 .

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

A. Levin, K. Mahaffey, M. Jardine, 2023, Diabetes, obesity & metabolism.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

B. Zinman, C. Cannon, B. Brenner, 2019, The New England journal of medicine.

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

B. Zinman, A. Levin, K. Mahaffey, 2023, BMJ Open Diabetes Research & Care.

Discontinuation of Renin-Angiotensin System Inhibitors and Clinical Outcomes in Chronic Kidney Disease: A Systemic Review and Meta-Analysis

J. Lv, Xu-jie Zhou, S. Shi, 2023, American Journal of Nephrology.

The impact of canagliﬂozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial

K. Mahaffey, M. Jardine, V. Perkovic, 2022 .